DK2037899T3 - Nanopartikler til nukleinsyreafgivelse - Google Patents
Nanopartikler til nukleinsyreafgivelseInfo
- Publication number
- DK2037899T3 DK2037899T3 DK07764504.2T DK07764504T DK2037899T3 DK 2037899 T3 DK2037899 T3 DK 2037899T3 DK 07764504 T DK07764504 T DK 07764504T DK 2037899 T3 DK2037899 T3 DK 2037899T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- acid delivery
- delivery nanoparticles
- nanoparticles
- chitosan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81920906P | 2006-07-07 | 2006-07-07 | |
| PCT/DK2007/050084 WO2008003329A2 (en) | 2006-07-07 | 2007-07-06 | Nanoparticles for nucleic acid delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2037899T3 true DK2037899T3 (da) | 2011-05-09 |
Family
ID=38754461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07764504.2T DK2037899T3 (da) | 2006-07-07 | 2007-07-06 | Nanopartikler til nukleinsyreafgivelse |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100015232A1 (da) |
| EP (3) | EP2037899B1 (da) |
| AT (1) | ATE503469T1 (da) |
| CA (1) | CA2706124A1 (da) |
| DE (1) | DE602007013559D1 (da) |
| DK (1) | DK2037899T3 (da) |
| ES (1) | ES2362376T3 (da) |
| WO (1) | WO2008003329A2 (da) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875449B2 (en) | 2006-09-15 | 2011-01-25 | Fmc Biopolymer As | Oligonucleotide non-viral delivery systems |
| WO2009048958A2 (en) * | 2007-10-08 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Methods and compositions involving chitosan nanoparticles |
| EP3252068B1 (en) | 2009-10-12 | 2025-07-02 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| FR2963351B1 (fr) * | 2010-07-30 | 2013-03-08 | Univ Claude Bernard Lyon | Particules formees d'un complexe polyelectrolyte de chitosane et d'un polysaccharide anionique, presentant une stabilite amelioree |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012094574A2 (en) * | 2011-01-06 | 2012-07-12 | The Johns Hopkins University | Stabilized polyribonucleotide nanoparticles |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| EP2694042A4 (en) * | 2011-04-04 | 2015-06-10 | Univ Nebraska | Activated Nucleoside Analog Conjugates and Methods of Use |
| US20150087689A1 (en) | 2011-05-24 | 2015-03-26 | Polyvalor, Limited Partnership | COMPOSITIONS AND METHODS FOR EFFICACIOUS AND SAFE DELIVERY OF siRNA USING SPECIFIC CHITOSAN-BASED NANOCOMPLEXES |
| US8841272B2 (en) * | 2011-05-31 | 2014-09-23 | Kansas State University Research Foundation | Double-stranded RNA-based nanoparticles for insect gene silencing |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| WO2014039627A1 (en) | 2012-09-05 | 2014-03-13 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
| US9801953B2 (en) | 2012-10-15 | 2017-10-31 | Emory University | Nanoparticles carrying nucleic acid cassettes for expressing RNA |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| DK3019619T3 (da) | 2013-07-11 | 2021-10-11 | Modernatx Inc | Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| EP3151856B1 (en) * | 2014-06-06 | 2019-08-07 | Merck Patent GmbH | Antigen-loaded chitosan nanoparticles for immunotherapy |
| WO2016011222A2 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US9724307B2 (en) | 2015-02-24 | 2017-08-08 | San Heh Pharmaceutical Corporation | Crosslinked nanoparticle composition |
| US12109274B2 (en) | 2015-09-17 | 2024-10-08 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| BR112018071997A2 (pt) * | 2016-04-26 | 2019-02-12 | Viaqua Therapeutics Ltd | nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico |
| WO2017223176A1 (en) | 2016-06-24 | 2017-12-28 | Modernatx, Inc. | Methods and apparatus for filtration |
| EP3552632B1 (en) * | 2016-12-07 | 2023-07-12 | Stelic Institute & Co., Inc. | Medicinal composition for treating and preventing inflammatory bowel disease |
| BR112020020870A2 (pt) | 2018-07-03 | 2021-04-06 | Embrapa-Empresa Brasileira De Pesquisa Agropecuaria | Pesticida |
| CN110396524B (zh) * | 2019-05-31 | 2023-05-02 | 海南大学 | 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途 |
| KR102604882B1 (ko) * | 2021-07-01 | 2023-11-21 | 인천대학교 산학협력단 | 신규 특이적 항암 및 항염증 siRNA 및 이의 용도 |
| WO2023084510A1 (en) | 2021-11-09 | 2023-05-19 | Viaqua Therapeutics Ltd. | Compositions for aquaculturing |
| IT202100032393A1 (it) | 2021-12-23 | 2023-06-23 | Torino Politecnico | Metodo per la preparazione di nanoparticelle polimeriche ibride per il rilascio di farmaci oligonucleotidici nelle terapie farmacologiche a scopo rigenerativo, curativo e preventivo |
| CN115992131A (zh) * | 2022-07-22 | 2023-04-21 | 江苏省农业科学院 | 一种纳米化壳聚糖/dsGRK复合体及其制备方法和应用 |
| WO2024182707A1 (en) | 2023-03-02 | 2024-09-06 | Krystal Biotech, Inc. | Interleukin-2 and interleukin-12 for cancer therapy |
| CN118304423B (zh) * | 2023-05-25 | 2024-10-11 | 无锡市第二人民医院 | 多层级壳聚糖明胶颗粒载P4HA1 siRNA通过抑制细胞EMT治疗脑胶质瘤的研究 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| NO317653B1 (no) * | 2002-05-03 | 2004-11-29 | Stiftelsen Biopolymer | Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav. |
| AU2003279004B2 (en) * | 2002-09-28 | 2009-10-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
| US20050013854A1 (en) * | 2003-04-09 | 2005-01-20 | Mannino Raphael J. | Novel encochleation methods, cochleates and methods of use |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| WO2005113770A1 (en) | 2004-05-13 | 2005-12-01 | Institut Gustave Roussy | Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them. |
| US7875449B2 (en) * | 2006-09-15 | 2011-01-25 | Fmc Biopolymer As | Oligonucleotide non-viral delivery systems |
-
2007
- 2007-07-06 ES ES07764504T patent/ES2362376T3/es active Active
- 2007-07-06 WO PCT/DK2007/050084 patent/WO2008003329A2/en not_active Ceased
- 2007-07-06 EP EP07764504A patent/EP2037899B1/en not_active Not-in-force
- 2007-07-06 US US12/307,566 patent/US20100015232A1/en not_active Abandoned
- 2007-07-06 AT AT07764504T patent/ATE503469T1/de not_active IP Right Cessation
- 2007-07-06 DK DK07764504.2T patent/DK2037899T3/da active
- 2007-07-06 CA CA2706124A patent/CA2706124A1/en not_active Abandoned
- 2007-07-06 EP EP11167103A patent/EP2397123A1/en not_active Withdrawn
- 2007-07-06 DE DE602007013559T patent/DE602007013559D1/de active Active
- 2007-07-06 EP EP10187562A patent/EP2295045A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2397123A1 (en) | 2011-12-21 |
| CA2706124A1 (en) | 2008-01-10 |
| WO2008003329A3 (en) | 2008-02-21 |
| ES2362376T3 (es) | 2011-07-04 |
| DE602007013559D1 (de) | 2011-05-12 |
| ATE503469T1 (de) | 2011-04-15 |
| US20100015232A1 (en) | 2010-01-21 |
| EP2295045A1 (en) | 2011-03-16 |
| EP2037899B1 (en) | 2011-03-30 |
| WO2008003329A2 (en) | 2008-01-10 |
| EP2037899A2 (en) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2037899T3 (da) | Nanopartikler til nukleinsyreafgivelse | |
| WO2008151022A3 (en) | Nucleic acid nanoparticles and uses therefor | |
| WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
| HK1200837A1 (en) | Compositions and methods for silencing aldehyde dehydrogenase | |
| WO2013143700A3 (en) | Artificial nucleic acid molecules comprising a 5'top utr | |
| WO2008115851A3 (en) | Rnai therapeutic for respiratory virus infection | |
| WO2009134487A3 (en) | Optimized methods for delivery of dsrna targeting the pcsk9 gene | |
| WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
| WO2010014895A3 (en) | Nanoparticle compositions for nucleic acids delivery system | |
| EP4385568A3 (en) | Compositions and methods for inhibiting expression of cd274/pd-l1 gene | |
| WO2009129465A3 (en) | Compositions and methods for inhibiting expression of xbp-1 gene | |
| WO2009129319A3 (en) | Silencing of csn5 gene expression using interfering rna | |
| WO2013165816A3 (en) | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS | |
| WO2006110688A3 (en) | Rnai therapeutic for respiratory virus infection | |
| EP4279610A3 (en) | Ribonucleic acid purification | |
| WO2010048228A3 (en) | Compositions and methods for inhibiting expression of transthyretin | |
| HK1208227A1 (en) | Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides | |
| WO2008134761A3 (en) | Modification of biological targeting groups for the treatment of cancer | |
| HK1203077A1 (en) | Modified nucleoside, nucleotide, and nucleic acid compositions | |
| WO2012024526A3 (en) | Conjugates, particles, compositions, and related methods | |
| WO2010018563A3 (en) | Compositions and methods for the prognosis of lymphoma | |
| WO2009108217A3 (en) | Compositions comprising k-ras sirna and methods of use | |
| MX2014006136A (es) | Uso de aril- y hetarilcarboxamidas como endoparasiticidas. | |
| LT3098239T (lt) | Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui | |
| WO2007131495A3 (de) | Multimer zur immunstimulation |